FGEN Live signals | Maximize Profits with Getagraph.com

BUY 102167 min ago

@ $2.26

Issued: 14 Feb 2024 @ 15:55

Return: -54.87%

Previous signal: Feb 14 - 15:23

Previous signal: Sell

Return: -2.38 %

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 15:43):

Stats
Today's Volume	963 162
Average Volume	2.81M
Market Cap	100.75M
EPS	$0 ( 2024-02-26 )
Next earnings date	( $0 ) 2024-05-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.350
ATR14	$0.00600 (0.59%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-22	Adib Deyaa	Sell	0	Common Stock
2024-04-22	Adib Deyaa	Sell	300 000	Stock Option (Right to Buy)
2024-03-22	Wettig Thane	Sell	782	Common Stock
2024-03-07	Wettig Thane	Buy	50 000	Common Stock
2024-03-06	Graham Juan	Buy	781	Common Stock

INSIDER POWER
64.64
Last 100 transactions
Buy: 2 904 321 \| Sell: 578 976

Volume Correlation

Long: 0.04 (neutral)

Short: -0.69 (moderate negative)

Signal:(49.718) Neutral

FibroGen Inc Correlation

10 Most Positive Correlations
FCBP	0.909
SMMT	0.904
CCOI	0.901
FGM	0.897
YQ	0.893
FEP	0.89
EUFN	0.889
BNIXU	0.887
CID	0.887
NIU	0.886

10 Most Negative Correlations
PCRX	-0.904
SLDP	-0.891
MARK	-0.887
PFBI	-0.887
WKSP	-0.885
RCMT	-0.884
NTLA	-0.882
ONDS	-0.875
LARK	-0.875
RDHL	-0.869

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

FibroGen Inc Correlation - Currency/Commodity

0.00
( neutral )

0.23
( neutral )

0.00
( neutral )

-0.11
( neutral )

FibroGen Inc Financials

Annual	2023
Revenue:	$147.75M
Gross Profit:	$128.90M (87.24 %)
EPS:	$-2.92

Q4	2023
Revenue:	$27.14M
Gross Profit:	$21.73M (80.08 %)
EPS:	$-0.570

Q3	2023
Revenue:	$40.13M
Gross Profit:	$35.89M (89.43 %)
EPS:	$-0.650

Q2	2023
Revenue:	$44.32M
Gross Profit:	$38.61M (87.12 %)
EPS:	$-0.900

Financial Reports:

No articles found.

FibroGen Inc

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.